SCHEMBL3230207

SCHEMBL3230207

CN1CCN(c2ccc3ccccc3c2)c2ccc(-c3cnccn3)cc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.46
SLC6A3 Q01959 4/20 0.46
SLC6A4 P31645 3/20 0.46
SCN9A Q15858 1/20 0.45
HTR3A P46098 1/20 0.41
CYP17A1 P05093 1/20 0.39
DYRK1A Q13627 4/20 0.39
DHFR P00374 1/20 0.39
GSK3B P49841 2/20 0.38
MET P08581 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36
RAB9A P51151 1/20 0.36
KLF5 Q13887 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3220973 0.89 SCN9A (0.49) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3234067 0.88 SCN9A (0.46) SLC6A2SLC6A3SLC6A4SCN9ADYRK1A
SCHEMBL3226065 0.87 SCN9A (0.45) SLC6A2SLC6A3SLC6A4SCN9ADYRK1A
SCHEMBL3227316 0.85 SLC6A2 (0.45) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3233121 0.85 CYP11B1 (0.50) SCN9AHTR3ACYP17A1
SCHEMBL3229955 0.84 SCN9A (0.44) SLC6A2SLC6A3SLC6A4SCN9ADYRK1A
SCHEMBL3232265 0.84 SCN9A (0.42) SLC6A2SLC6A3SLC6A4SCN9ADYRK1A
SCHEMBL3222166 0.84 SCN9A (0.47) SLC6A2SLC6A3SLC6A4SCN9ADYRK1A
SCHEMBL3225109 0.84 SLC6A2 (0.48) SLC6A2SLC6A3SLC6A4SCN9ADYRK1A
SCHEMBL3235442 0.84 SCN9A (0.46) SCN9AHTR3ACYP17A1CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US claimed
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A2 28/4885SLC6A3 32/4885SLC6A4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.